Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1996-3-25
|
| pubmed:abstractText |
We report the detection of activated GP IIb-IIIa complexes on platelets of patients undergoing thrombolytic therapy after acute myocardial infarction. Protocols were established for the monoclonal antibodies (mAbs): VH10, anti-P-selectin, a marker of platelet secretion; 9F9 and F26, two anti-RIBS (receptor-induced binding sites) mAbs specific for fibrinogen (Fg) bound to the GP IIb-IIIa receptor. Of ten patients studied: two were treated with streptokinase, four with APSAC (anisoylated plasminogen-streptokinase activator complex), and three with rt-PA. Platelets were tested on at least five occasions in the week following therapy. The percentage of platelets positive with 9F9 was often high, and reached a maximum within three days. By this time, plasma Fg levels, which fell during fibrinolysis, had begun to return to normal. Levels of activated platelets had fallen to baseline after 7 days. PAC-1, a mAb which binds directly to the activated GP IIb-IIIa complex, confirmed the results with 9F9, but F26 was a less sensitive probe. Binding of the anti-P-selectin mAb (VH10) was low, showing that little secretion had occurred. A concentration-dependent inhibition of 9F9 binding by RGDW peptide, a competitive inhibitor for Fg on GP IIb-IIIa, confirmed that Fg (or epitope-containing degradation products) were being located by the antibody. The activation of GP IIb-IIIa occurred despite the patients receiving aspirin and heparin. Thus platelets of some fibrinolytic patients have an increased tendency for surface activation within the first 72 h after treatment, a finding which would be compatible with an increased thrombotic tendency.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anistreplase,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Streptokinase,
http://linkedlifedata.com/resource/pubmed/chemical/Tissue Plasminogen Activator
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0957-5235
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
6
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
395-410
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8589205-Adult,
pubmed-meshheading:8589205-Aged,
pubmed-meshheading:8589205-Amino Acid Sequence,
pubmed-meshheading:8589205-Anistreplase,
pubmed-meshheading:8589205-Antibodies, Monoclonal,
pubmed-meshheading:8589205-Blood Platelets,
pubmed-meshheading:8589205-Female,
pubmed-meshheading:8589205-Flow Cytometry,
pubmed-meshheading:8589205-Humans,
pubmed-meshheading:8589205-Kinetics,
pubmed-meshheading:8589205-Male,
pubmed-meshheading:8589205-Middle Aged,
pubmed-meshheading:8589205-Molecular Sequence Data,
pubmed-meshheading:8589205-Myocardial Infarction,
pubmed-meshheading:8589205-Platelet Activation,
pubmed-meshheading:8589205-Platelet Count,
pubmed-meshheading:8589205-Platelet Membrane Glycoproteins,
pubmed-meshheading:8589205-Recombinant Proteins,
pubmed-meshheading:8589205-Streptokinase,
pubmed-meshheading:8589205-Thrombolytic Therapy,
pubmed-meshheading:8589205-Tissue Plasminogen Activator
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Flow cytometry reveals activated GP IIb-IIIa complexes on platelets from patients undergoing thrombolytic therapy after acute myocardial infarction.
|
| pubmed:affiliation |
Unité de Recherche Associée 1464 Centre National de la Recherche Scientifique, Institut Fédératif de Recherche Coeur-Vaisseaux-Thrombose, Hôpital Cardiologique, Pessac, France.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|